Study of immunotherapy for relapsed chest lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well two immunotherapy medicines—pembrolizumab alone or nivolumab combined with brentuximab vedotin—work for people with a type of lymphoma in the chest that has come back or not responded to treatment. It uses real-world data from patients who received these treatments outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with primary mediastinal B-cell lymphoma (a type of lymphoma that starts in the chest).
- Your lymphoma has come back or hasn't gotten better with previous treatments (relapsed/refractory).
- You have been treated with either: pembrolizumab (Keytruda) alone, or nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in a real-world setting (not in a clinical trial).
- You are willing to sign a consent form allowing your medical information to be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
This trial tests a fixed low dose of nivolumab combined with standard chemo-immunotherapy for people newly diagnosed with primary mediastinal B-cell lymphoma. The goal is to see if this combination is safe and effective.
This phase 2 study tests balstilimab to see if it can be safe and effective for certain lymphomas that came back or didn’t respond to standard treatment. If you qualify, you’ll be checked closely for side effects and how well your lymphoma responds.
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
Hear when a new Primary Mediastinal B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.